News :: Matinas BioPharma Holdings, Inc. (MTNB)

Matinas in the news.

May 11, 2020 • 4:05 PM EDT

Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights

May 4, 2020 • 7:00 AM EDT

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020

Apr 28, 2020 • 7:00 AM EDT

Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference

View all news

MAT9001: NOVEL OMEGA-3 FATTY ACID COMPOSITION

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

View

Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia

View

MAT2203: Encochleated formulation of amphotericin B

A Novel Encochleated Atovaquone Formulation is Active in a Murine Model of Pneumocystis Pneumonia

View

Efficacy of Oral Cochleate-Amphotericin B for the Prevention of Invasive Candidiasis in Neutropenic Mice

View

Oral Dosing of Encochleated Amphotericin B (CAmB): RapOral Dosing of Encochleated Amphotericin B (CAmB): Rapid Drug Targeting to Infected Tissues in Mice with Invasive Candidiasis; A-054: Mannino/Perlin: ICAAC 2015

View

Oral Administration of Amphotericin B (Oral Administration of Amphotericin B (CAmB) in Humans: a Phase I Study of Tolerability and Pharmacokinetics - Data showing results from Phase I clinical trial; Phase 1 SAD: Imedex’ “Focus on Fungal Infections” 2009**

View

Oral Administration of Amphotericin B: Toxicokinetic Studies in Animal Models - Data showing reduced toxicity of oral encochleated amphotericin B; 28-day Rat/Dog Tox: “Focus on Fungal Infections” 2009**

View

Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis; Antimicrob Agents Chemother. 2002 Aug; 46(8): 2704–2707

View

Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis; Antimicrob Agents Chemother. 2000 Sep; 44(9): 2356–2360

View

Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model; Antimicrob Agents Chemother. 2000 Jun; 44(6): 1463–1469

View

Efficacy in Mouse model of Cryptococcal Meningoencephalitis; Crypto slides: AIDS- Associated Mycoses scientific meeting, Capetown, July 2016

View

Efficacy of Oral Encochleated Amphotericin B (CAMB) in a Mouse Model of Cryptococcal Meningoencephalitis; Poster Presentation 189 ASM Microbe 2017

View

Oral Encochleated Amphotericin B (CAMB) in the Treatment of Chronic Azole Resistant Mucocutaneous Candidiasis; Poster Presentation 240 ASM Microbe 2017

View

MAT2501: Encochleated formulation of Amikacin

Oral Encochleated Amikacin Demonstrates Activity In Vitro and In Vivo In Biofilm Models of Mycobacterium avium; B-539: Lu/Mannino/ElliasBonitz/Bermudez: ICAAC 2015

View

ASTMH 2012 - Data showing the ability of cochleates to deliver aminoglycosides orally was presented at the 2012 American Society of Tropical Medicine and Hygiene conference; LB-176: Mannino/Lu/Bonitz/Bermudez: ASTMH 2012 (Am.Soc.Trop.Med.Hyg.)

View

Other Cochleate Technology Data

IDWeek 2016 Poster - Formulation of Orally and Intranasally Administered Influenza Vaccine in Cochleate Lipid-Crystal Nano-Particles Significantly Enhances Immune Response in Murine Models of Influenza; IDweek 2016 flu vaccine poster

View

Biotech 2012 Innovation Corridor - Our technology was featured at the Biotech 2012 Innovation Corridor for the demonstrated ability to orally deliver antimicrobial drugs. Our poster was selected as one of the winners by a panel of judges; Biotech 2012 Corridor: technology poster

View

Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl- s-Triazole Derivative in a Murine Model of Graft-Versus- Host Disease; Transplantation. 2008 Jul 15;86(1):171-5. doi: 10.1097/TP.0b013e31817ba761

View

Pharmacokinetics and Efficacy of Encochleated Atovaquone (CATQ) in Murine Model of Pneumocystis; IDweek 2015 Poster presentation CATQ by NIH

View

10 mg /Kg lung (outlier) Lipid-Crystal Nano-Particles: Formulation and Delivery of Oligonucleotides; CHI April 2016 Boston conference Poster on “oligonucleotides”

View

Formulation of Ibuprofen in Lipid-Crystal Nano-Particles Enhances Efficacy and Reduces Gastric Mucosal Erosions in a Rat Carrageenan-induced Paw Inflammation Model; EULAR June 2016 abstract on encochleated Ibuprofen

View

Efficacious and Commercially Viable DNA Vaccines: Plasmids Formulated into Lipid-Crystal Nano-Particles for Oral and Systemic Immunization; ECCMID April 2017 Poster on DNA plasmid vaccines

View

PAST EVENTS

May 11 2020

Quarterly Update Conference Call and Webcast

Webcast Related Materials

May 5 2020

Maxim Group Infectious Disease Virtual Conference

Related Materials

Apr 23 2020

2020 Virtual Investor Summit

Webcast Related Materials

View All Events